Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Sells $23,864.58 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) General Counsel Benjamin Landry sold 6,057 shares of the company's stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $3.94, for a total transaction of $23,864.58. Following the completion of the sale, the general counsel now owns 151,125 shares of the company's stock, valued at approximately $595,432.50. This represents a 3.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Health Catalyst Price Performance

Shares of HCAT stock traded up $0.02 on Thursday, reaching $3.98. The company had a trading volume of 656,609 shares, compared to its average volume of 604,720. The business's 50-day moving average is $3.94 and its 200 day moving average is $5.30. Health Catalyst, Inc. has a one year low of $3.49 and a one year high of $9.24. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $277.01 million, a PE ratio of -2.95 and a beta of 1.53.

Analyst Ratings Changes

A number of analysts recently issued reports on HCAT shares. Royal Bank of Canada lowered their target price on Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating for the company in a research note on Thursday, February 27th. Citigroup cut their price objective on shares of Health Catalyst from $7.00 to $6.50 and set a "buy" rating on the stock in a research report on Friday, April 25th. Evercore ISI cut Health Catalyst from an "outperform" rating to an "inline" rating in a report on Wednesday, April 9th. Stifel Nicolaus lifted their target price on Health Catalyst from $5.00 to $5.50 and gave the company a "hold" rating in a research report on Thursday, May 8th. Finally, Canaccord Genuity Group cut their target price on Health Catalyst from $10.00 to $9.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $8.00.

Institutional Trading of Health Catalyst

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Quantbot Technologies LP bought a new stake in Health Catalyst during the 4th quarter worth $29,000. Group One Trading LLC boosted its stake in shares of Health Catalyst by 107.6% during the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company's stock valued at $31,000 after purchasing an additional 2,260 shares in the last quarter. Focus Partners Wealth bought a new stake in shares of Health Catalyst during the first quarter worth about $46,000. XTX Topco Ltd bought a new stake in shares of Health Catalyst during the first quarter worth about $54,000. Finally, Aquatic Capital Management LLC acquired a new position in shares of Health Catalyst in the fourth quarter valued at approximately $63,000. Institutional investors own 85.00% of the company's stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.